COPENHAGEN, Denmark — Bavarian Nordic A/S has announced the initiation of the first Phase 2 clinical study of MVA-BN RSV, its novel, broad spectrum, vaccine candidate against RSV (respiratory syncytial virus). The study, which is being conducted in the U.S., will enrol 400 healthy subjects, aged 55 or older who will be randomized into five…